The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy.
- Author:
Sang Joon SHIN
1
;
Min Kyoung KIM
;
Kyung Hee LEE
;
Myung Soo HYUN
;
Sang Woon KIM
;
Sun Kyo SONG
;
Sung Hwa BAE
;
Hun Mo RYOO
Author Information
1. Division of Hematology-oncology, Yeungnam University College of Medicine, Korea. hms@med. yu.ac.kr
- Publication Type:Original Article
- Keywords:
Stomach neoplasm;
Cisplatin;
Docetaxel
- MeSH:
Adenocarcinoma;
Appointments and Schedules;
Cisplatin*;
Creatinine;
Drug Therapy*;
Drug Therapy, Combination*;
Fluorouracil*;
Follow-Up Studies;
Humans;
Liver;
Neutropenia;
Premedication;
Stomach Neoplasms*;
Survival Rate
- From:Cancer Research and Treatment
2004;36(6):367-371
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer. MATERIALS AND METHODS: Patients with measurable gastric adenocarcinoma received intravenous docetaxel 75 mg/m2 and cisplatin 75 mg/m2 with premedication on day 1, which was repeated every 3 weeks. All patients received DP as a second-line treatment after failing to 5-FU based chemotherapy. RESULTS: 34 patients were enrolled in this study between January 1998 and August 2003. A total of 112 cycles (median 3 cycles) were administered. Responses were evaluable in 30 patients. The objective response rate was 16.7% (95% CI: 3.5~30.3), with a stable disease in 56.7% (95% CI: 40.0~74.4) and a progressive disease in 26.7% (95% CI: 10.9~42.5) of patients, with a median follow up duration of 20 months for all the patients, The median duration of response, time to progression and overall survival were 2.1 months (95% CI: 0.4~3.9), 4.2 months (95% CI: 2.3~6.1) and 6.8 months (95% CI: 1.3~12.3), respectively, with a 1-year survival rate of 32%. The toxicity was evaluated in 30 patients, with neutropenia being most common. Renal impairment was seen in two patients with grade 3 creatinine elevation and liver enzyme elevation in four with grades 3 and 4. CONCLUSION: Although DP was an active combination regimen, with a tumor control rate of about 73% and with moderate tolerance, adjustment of the administration schedule, with further evaluation of other combination chemotherapies of docetaxel with new agents, other than cisplatin, seem warranted.
